Baseline characteristics of the patients
| OND | Multiple sclerosis | |||||
|---|---|---|---|---|---|---|
| NfHSMI35 | NfHSMI34 | Ratio‡ | All | SP/PP† | RR | |
| ‡The “ratio” of NfHSMI34 to NfHSMI35 was available for only a subgroup of patients due to restricted sample volume. | ||||||
| *Values are median (interquartile range). | ||||||
| †Patients with SP/PP disease had a longer disease duration (p<0.05) and relapse free interval (p<0.05). | ||||||
| N/A, not applicable; NfHSMI34, NfH detected with SMI34 antibody; NfHSMI35, NfH detected with SMI35 antibody; OND, other neurological diseases; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive. | ||||||
| Number | 271 | 119 | 60 | 34 | 23 | 11 |
| Female:male | 155:116 | 61:58 | 32:28 | 15:19 | 11:12 | 4:7 |
| Age (years)* | 44.0 (1–77.9) | 45.4 (34.9–52.9) | 47.2 (42.5–51.5) | 46.5 (42.5–51.5) | 48.5 (42.5–51.5) | 39.6 (34.9–47.7) |
| Disease duration (years)* | N/A | N/A | N/A | 14.0 (8.0–19.9) | 16.0 (11.8–21.8) | 8.1 (3.7–13.0) |
| Relapse free interval (months)* | N/A | N/A | N/A | 38.0 (8.0–96.0) | 83.0 (23.5–144.5) | 8.0 (3.0–38.0) |